{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fproactive-interviews-for-investors.simplecast.com%2Fepisodes%2F20260722-hvivo-plc-lHDC1w93","width":444,"version":"1.0","type":"rich","title":"hVIVO order book tops £65m as CEO backs strong H2 recovery","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/92f9cc71-7d4c-4ec0-a2f3-6a6b31027b4c/3fd3b604-35cf-4701-acde-0f1fdf33d67a/square-with-type.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"hVIVO PLC (AIM: HVO) CEO Yamin 'Mo' Khan joined Proactive's Stephen Gunnion to discuss the company's latest trading update, highlighting a record order book of more than £65 million that supports expectations for a much stronger second half of 2026.\n\nKhan explained why first-half revenue of around £16.3 million and a modest adjusted EBITDA loss were always expected, with contract wins weighted towards the second half of the year. He said one of the company's strongest-ever periods of new business, following the launch of its integrated clinical development platform, has extended revenue visibility into 2027 and 2028.\n\nThe interview also explored a 45% increase in inbound requests for proposals, reflecting growing demand across a broader range of services, including human challenge studies, early-phase clinical trials, laboratory services and consulting.\n\nKhan discussed how hVIVO has evolved from a specialist human challenge CRO into a diversified clinical research business capable of delivering end-to-end programmes, while pointing to improving biotech funding conditions as a positive backdrop for future growth.\n\nFor more interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future updates.\n\nRead Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy\n\n#hVIVO #HVO #clinicalresearch #CRO #challengetrials #infectiousdisease #biotech #UKstocks #smallcap #investing"}